Showing results (1-10 of 75) with videos related to

Sort By:
Pageof 8
Contemporary Clinical Trials|March 29, 2026
Internal pilot sample size re-estimation for the B-free trial: A case study of a cluster randomized crossover trialShun-Fu Lee, Keyun Zhou, Jessica Spence
Diabetes Research and Clinical Practice|November 13, 2023
Sex hormone-binding globulin and heart failure hospitalizations in patients with dysglycemia: Experiences from the outcome reduction with an Initial Glargine Intervention trialAnne Wang, Sibylle Hess, Shun Fu Lee, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 16, 2026
An Empirical Comparison of Statistical Methods for Estimating Treatment Effects on EQ-5D in Randomized Clinical TrialsJiajun Yan, Brittany Humphries, Menglu Che, et al.
American Heart Journal|September 7, 2016
Utility of the LACE index at the bedside in predicting 30-day readmission or death in patients hospitalized with heart failurePayam Yazdan-Ashoori, Shun Fu Lee, Quazi Ibrahim, et al.
The Journal of Clinical Endocrinology and Metabolism|April 4, 2017
Validation of the ORIGIN Cardiovascular Biomarker Panel and the Value of Adding Troponin I in Dysglycemic PeopleHertzel C Gerstein, Guillaume Paré, Matthew J McQueen, et al.
American Heart Journal|December 6, 2019
Variations in stepped-wedge cluster randomized trial design: Insights from the Patient-Centered Care Transitions in Heart Failure trialRudy R Unni, Shun Fu Lee, Lehana Thabane, et al.
Diabetes, Obesity & Metabolism|July 3, 2026
A Highly Powered Large Outcomes Randomised Controlled Trial Will Usually, but Not Always, Have Balanced Groups at BaselineHertzel C Gerstein, Zayeeda Labiba, Sibylle Hess, et al.
Journal of Alzheimer'S Disease : JAD|April 18, 2022
Biomarkers of Prevalent and Incident Cognitive Dysfunction in People with Dysglycemia: Data from the ORIGIN TrialTali Cukierman-Yaffe, Shun-Fu Lee, Guillaume Pare, et al.
Journal of Clinical Epidemiology|February 9, 2021
Patient reported outcome measures in clinical trials should be initially analyzed as continuous outcomes for statistical significance and responder analyses should be reserved as secondary analysesDavid Collister, Shrikant Bangdiwala, Michael Walsh, et al.
Diabetes, Obesity & Metabolism|May 15, 2024
Determinants of serious health outcome-free status in middle-aged and older people with dysglycaemia: Exploratory analysis of the ORIGIN trialKamel Mohammedi, Sibylle Hess, Matthew McQueen, et al.
Pageof 8